Publications & Posters

2019 Top Simoa Peer-Reviewed Articles

ALS – Frontotemporal Dementia – Dementia

Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.
Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, et. al.
European Journal of Neurology. 2019. doi: 10.1111/ene.14063.

Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis.
Leoni E, Bremang M, Mitra V, Zubiri I, et. al.
Sci Rep. 2019;9:4478. doi: 10.1038/s41598-019-40632-4.

Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.
Wilke C, Pujol-Calderón F, Barro C, Stransky E, et. al.
Clin Chem Lab Med. 2019. doi: 10.1515/cclm-2019-0015.

Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.
van der Ende EL, Meeter LH, Poos JM, Panman JL, et. al.
The Lancet Neurology. 2019;18:1103-1111. doi: 10.1016/S1474-4422(19)30354-0.

Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.
Pase MP, Beiser AS, Himali JJ, Satizabal CL, et. al.
JAMA Neurol. 2019. doi: 10.1001/jamaneurol.2018.4666.

Alzheimer’s Disease

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease.
Preische O, Schultz SA, Apel A, Kuhle J, et. al.
Nature Medicine. 2019. doi: 10.1038/s41591-018-0304-3.

The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.
Holth JK, Fritschi SK, Wang C, Pedersen NP, et. al.
Science (New York, NY). 2019. doi: 10.1126/science.aav2546.

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N, Cullen NC, Andreasson U, Zetterberg H and Blennow K.
JAMA Neurol. 2019. doi: 10.1001/jamaneurol.2019.0765.

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.
Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, et. al.
JAMA Neurol. 2019. doi: 10.1001/jamaneurol.2019.1632.

Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging.
Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, et. al.
JAMA Neurol. 2019. doi:10.1001/jamaneurol.2019.2462.

Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy.
Wu T, Dejanovic B, Gandham VD, Gogineni A, et. al.
Cell Rep. 2019;28:2111-2123.e6. doi: 10.1016/j.celrep.2019.07.060.

Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease.
Chatterjee P, Zetterberg H, Goozee K, Lim CK, et. al.
Journal of Neuroinflammation. 2019;16:186. doi: 10.1186/s12974-019-1567-4.

Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report.
Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, et. al.
Nature Medicine. 2019;25:1680-1683. doi: 10.1038/s41591-019-0611-3.

Cancer- Gynegological

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA, McCollum M, Davidson BA, Broadwater G, et. al.|
Gynecologic Oncology. 2019. doi: 10.1016/j.ygyno.2019.03.246.

Cancer – Rectal

Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response.
Canto LMD, Cury SS, Barros-Filho MC, Kupper BEC, et. al.
Sci Rep. 2019;9:8702. doi: 10.1038/s41598-019-45151-w.


Prospective Clinical Trial Measuring the Effects of Cardiopulmonary Bypass Under Mild Hypothermia on the Inflammatory Response and Regulation of Cold-Shock Protein RNA-Binding Motif 3.
Rosenthal LM, Tong G, Wowro S, Walker C, et. al.
Therapeutic Hypothermia and Temperature Management. 2019. doi: 10.1089/ther.2018.0038. 

Charcot-Marie Tooth Disease

Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy.
Schiza N, Georgiou E, Kagiava A, Médard JJ, et. al.
Brain : A Journal of Neurology. 2019. doi: 10.1093/brain/awz064.

Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.

Kagiava A, Richter J, Tryfonos C, Karaiskos C, et. al.
Human Molecular Genetics. 2019. doi: 10.1093/hmg/ddz199.

Cognitive Performance

Cytokines are Associated with Longitudinal Changes in Cognitive Performance Among Urban Adults.
Beydoun MA, Weiss J, Obhi H, Beydoun HA, et. al.
Brain Behav Immun. 2019. doi: 10.1016/j.bbi.2019.04.027.

Creutzfeldt-Jakob Disease 

Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease.
Staffaroni AM, Kramer AO, Casey M, Kang H, et. al.
JAMA Neurol. 2019.doi: 10.1001/jamaneurol.2019.1071. 


Systemic inflammation is associated with depressive symptoms differentially by sex and race: a longitudinal study of urban adults.

Beydoun MA, Obhi HK, Weiss J, Canas JA, et. al.
Molecular Psychiatry. 2019. doi: 10.1038/s41380-019-0408-2. 

Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.
Carboni L, McCarthy DJ, Delafont B, Filosi M, et. al.
Translational Psychiatry. 2019;9:182. doi:  10.1038/s41398-019-0521-7.

Down’s Syndrome

Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients.
Shinomoto M, Kasai T, Tatebe H, Kondo M, et. al.
PLoS One. 2019;14:e0211575. doi: 10.1371/journal.pone.0211575. 

Plasma Neurofilament Light and Alzheimer’s Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS, Donohue MC, Matthews DC, Muranevici G, et. al.
Journal of Alzheimer’s Disease : JAD. 2019. doi: 10.3233/JAD-190322.

Plasma amyloid and tau as dementia biomarkers in Down syndrome: systematic review and meta-analyses.

Alhajraf F, Ness D, Hye A and Strydom A.
Developmental Neurobiology. 2019. doi: 10.1002/dneu.22715.

Infectious Disease

Alterations in Phosphorylation of Hepatocyte Ribosomal Protein S6 Control Plasmodium Liver Stage Infection.
Glennon EKK, Austin LS, Arang N, Kain HS, et. al.
Cell Rep. 2019;26:3391-3399.e4. doi: 10.1016/j.celrep.2019.02.085.

Ischemic Stroke

Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke.
Onatsu J, Vanninen R, Jäkälä P, Mustonen P, et. al.
Journal of Stroke and Cerebrovascular Diseases : The Official Journal of National Stroke Association. 2019. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008.

NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke.
Uphaus T, Bittner S, Gröschel S, Steffen F, et. al.
Stroke. 2019:Strokeaha119026410. doi: 10.1161/STROKEAHA.119.026410.

Macular Edema/Degeneration 

Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
Felfeli T, Juncal VR, Hillier RJ, Mak MY, et. al.
American journal of ophthalmology. 2019. doi: 10.1016/j.ajo.2019.04.002.

Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor.
Göpfert JC, Reiser A, Yañez VC, Pohle A, et. al.
Bioanalysis. 2019. doi: 10.4155/bio-2019-0044. 


Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism.
Scheiman J, Luber JM, Chavkin TA, MacDonald T, et. al.
Nature Medicine. 2019. doi:10.1038/s41591-019-0485-4.

Multiple Sclerosis

Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders.

Mariotto S, Ferrari S, Gastaldi M, Franciotta D, et. al.
Journal of Neurolgy, Neurosurgery, and Psychiatry. 2019. doi:

Neurofilament makes light of MS treatment monitoring.
Fyfe I.
Nature Reviews Neurology. 2019. doi:10.1038/s41582-019-0156-6.

Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.

Hyun JW, Kim Y, Kim G, Kim SH and Kim HJ.
Multiple Sclerosis (Houndsmills, Basingstoke, England). 2019. 135245851980757. doi: 10.1177/1352458519840757. 

Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.
Rotstein D and Montalban X.
Nature Reviews Neurology. 2019. doi: 10.1038/s41582-019-0170-8.

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.
Cantó E, Barro C, Zhao C, Caillier SJ, et. al.
JAMA Neurology. 2019. doi: 10.1001/jamaneurol.2019.2137. 

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.
Akgun K, Kretschmann N, Haase R, Proschmann U, et. al.
Neurology, neuroimmunology & Neuroinflammation. 2019;6:e555. doi: 10.1212/NXI.0000000000000555.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
Jakimovski D, Kuhle J, Ramanathan M, Barro C, et. al.
Ann Clin Transl Neurol. 2019. doi: 10.1002/acn3.50872.

Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation.

Baldassari LE, Planchon SM, Bermel RA, Nakamura K,  et. al.
Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2019;5:2055217319887198. doi: 10.1177/2055217319887198.

Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
Bjornevik K, Munger KL, Cortese M, Barro C, et. al.
JAMA Neurol. 2019. doi:  10.1001/jamaneurol.2019.3238.

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M, Nakamura Y, Michalak Z, Isobe N, et. al.
Neurology. 2019. doi: 10.1212/WNL.0000000000008160.

EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency.
Kjaer IM, Olsen DA, Alnor A, Brandslund I, et. al.
Clin Chem Lab Med. 2019. doi: 10.1515/cclm-2019-0376.

Osteoarthritis- Rheumatology 

Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-alpha signalling.
Melki I, Devilliers H, Gitiaux C, Bondet V, et. al.
Rheumatology (Oxford, England). 2019. doi: 10.1093/rheumatology/kez525.

A Phase 2 Trial of Lutikizumab, an Anti-Interleukin 1alpha/beta Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis.
Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, et. al.
Arthritis & Rheumatology (Hoboken, NJ). 2019. doi: 10.1002/art.40840.

Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles.
Reynolds JA, Briggs TA, Rice GI, Darmalinggam S, et. al.
Arthritis Research & Therapy. 2019;21:147. doi: 10.1186/s13075-019-1929-4.

Parkinson’s Disease

Plasma alpha-synuclein detected by single molecule array is increased in PD.

Ng ASL, Tan YJ, Lu Z, Ng EYL, et. al.
Annals of Clinical and Translational Neurology. 2019:0. doi:10.1002/acn3.729.

CSF and blood biomarkers for Parkinson’s disease.
Parnetti L, Gaetani L, Eusebi P, Paciotti S, et. al.
The Lancet Neurology. 2019. doi: 10.1016/S1474-4422(19)30024-9.


Posttraumatic stress disorder and total amyloid burden and amyloid-beta 42/40 ratios in plasma: Results from a pilot study of World Trade Center responders.
Clouston SAP, Deri Y, Diminich E, Kew R, et. al.
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2019;11:216-220. doi: 10.1016/j.dadm.2019.01.003

Spinocerebellar Ataxia

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.

Li QF, Dong Y, Yang L, Xie JJ, et. al.
Molecular Neurodegeneration. 2019;14:39. doi: 10.1186/s13024-019-0338-0.

Traumatic Brain Injury

Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity.

Winston CN, Romero HK, Ellisman M, Nauss S, et. al.
Frontiers in Neuroscience. 2019;13.2019. doi:10.3389/fnins.2019.01005

Characterisation of serum total tau following paediatric traumatic brain injury: a case-control study.
Stukas S, Higgins V, Frndova H, Gill J, et. al.
The Lancet Child & Adolescent Health. 2019. doi:

A serum protein biomarker panel improves outcome prediction in human traumatic brain injury.
Thelin EP, Al Nimer F, Frostell A, Zetterberg H, Blennow K, et. al.
J Neurotrauma. 2019. doi: 10.1089/neu.2019.6375.

Mild traumatic brain injuries with loss of consciousness are associated with increased inflammation and pain in military personnel.

Kanefsky R, Motamedi V, Mithani S, Mysliwiec V, et. al.
Psychiatry research. 2019;279:34-39. doi: 10.1016/j.psychres.2019.07.001.


Sensitivity and binding kinetics of an ultra-sensitive chemiluminescent enzyme-linked immunosorbent assay at arrays of antibodies.
Tobos C, Kim S, Rissin D, Johnson J, et. al.
Journal of Immunological Methods. 2019:112643-undefined. doi: 10.1016/j.jim.2019.112643.